Everolimus to treat aggressive retinal astrocytic hamartoma in tuberous sclerosis complex.

Authors :: Nallasamy N
Seider MI
Gururangan S
Mruthyunjaya P
Source :: Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus [J AAPOS] 2017 Aug; Vol. 21 (4), pp. 328-331. Date of Electronic Publication: 2017 Jul 18.
Publication Year :: 2017
Abstract: Retinal astrocytic hamartomas (RAH) are the most frequent ocular manifestation of tuberous sclerosis complex and are usually indolent, requiring only observation. We report an aggressive RAH subtype in a child unresponsive to anti-VEGF and laser therapy. Treatment with systemic everolimus was well-tolerated and significantly reduced ocular (and nonocular) tumor size and fluid exudation.<br /> (Copyright © 2017 American Association for Pediatric Ophthalmology and Strabismus. Published by Elsevier Inc. All rights reserved.)

Subjects :: Administration, Oral
Dose-Response Relationship, Drug
Drug Administration Schedule
Humans
Infant
Male
TOR Serine-Threonine Kinases antagonists & inhibitors
Everolimus administration & dosage
Immunosuppressive Agents administration & dosage
Retinal Diseases drug therapy
Tuberous Sclerosis drug therapy

Language :: English
ISSN :: 1528-3933
Volume :: 21
Issue :: 4
Database :: MEDLINE
Journal :: Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus
Publication Type :: Academic Journal
Accession number :: 28733147
Full Text :: https://doi.org/10.1016/j.jaapos.2017.04.012

Full Text Access

Tools